Patent US3993071A successfully refreshed from Google Patents.
US3993071A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Bioerodible ocular device
Assignee: Alza Corp
•
Filing: 1975-07-24
•
Granted: 1976-11-23
•
Expires: 1995-07-24
Abstract
Abstract An ocular insert for the continuous controlled administration of a predetermined therapeutically effective dosage of drug to the eye over a prolonged period of time. The device meters the flow of drug by means of a drug release rate controlling material. The insert bioerodes in the environment of the eye concurrently with the dispensing or at a point in time after the dispensing of the therapeutically desired amount of drug.
Inventors
- 👤 Takeru Higuchi
- 👤 Anwar A. Hussain
- 👤 John W. Shell
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 20:33
CPC Classifications
A; A61; A61F; A61F9/00; A61F9/0008; A61F9/0017; A61K; A61K9/00; A61K9/0012; A61K9/0048; A61K9/0051
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
151 words
A bioerodible ocular device defining a means for the controlled continuous administration of a predetermined dosage of drug to the eye, comprising a body of hydrophilic bioerodible drug release rate controlling material containing a water-insoluble drug formulation confined therein, the body being of an initial shape which is adapted for insertion and retention in the sac of the eye bounded by the surfaces of the bulbar conjunctiva of the sclera of the eyeball and the palpebral conjunctiva of the lid, the body being a means for continuously metering the flow of a therapeutically effective amount of drug to the eye at a controlled rate over a prolonged period of time in the range of from 8 hours to 30 days and wherein the body bioerodes in the environment of the eye concurrently with the dispensing or at a point in time after the dispensing of the therapeutically desired amount of drug.
Claim 2
Dependent Claim
151 words
A bioerodible ocular device defining a means for the controlled continuous administration of a predetermined dosage of drug to the eye, comprising a body of hydrophilic bioerodible drug release rate controlling material containing a water-insoluble drug formulation confined therein, the body being of an initial shape which is adapted for insertion and retention in the sac of the eye bounded by the surfaces of the bulbar conjunctiva of the sclera of the eyeball and the palpebral conjunctiva of the lid, the body being a means for continuously metering the flow of a therapeutically effective amount of drug to the eye at a controlled rate over a prolonged period of time in the range of from 8 hours to 30 days and wherein the body bioerodes in the environment of the eye concurrently with the dispensing or at a point in time after the dispensing of the therapeutically desired amount of drug.
Claim 3
Dependent Claim
33 words
The ocular device defined by claim 1 wherein the body dioerodes in the eye over a prolonged period of time in response to the environment in the eye by a process of solubilization.
Claim 4
Dependent Claim
36 words
The ocular device defined by claim 1 wherein the body bioerodes in the eye over a prolonged period of time in response to the environment in the eye by a process of hydrolysis, oxidation or reduction.
Claim 5
Dependent Claim
34 words
The ocular device defined by claim 1 wherein the body bioerodes in the eye over a prolonged period of time in response to the environment in the eye by a process of enzymatic cleavage.
Claim 6
Dependent Claim
22 words
The ocular device defined by claim 4 wherein the device contains an added enzyme to regulate the bioerosion rate of the device.
Claim 7
Dependent Claim
36 words
The ocular device defined by claim 1 wherein the body bioerodes in the eye over a prolonged period of time in response to the environment in the eye by a process of ion exchange or displacement.
Claim 8
Dependent Claim
32 words
The ocular device defined by claim 1 wherein the continuous dispensing of a metered amont of drug from the body to the eye is effected primarily through an erosion control release mechanism.
Claim 9
Dependent Claim
22 words
The ocular device defined by claim 1 wherein the prolonged period of time is an interval of from 1 to 8 days.
Claim 10
Dependent Claim
29 words
The ocular device defined by claim 1 wherein the body material bioerodes in the eye at a rate of from 0.1 milligrams per day to 15 milligrams per day.
Claim 11
Dependent Claim
30 words
The ocular device defined by claim 1 wherein the device contains an added agent to regulate the bioerosion rate selected from the group consisting of binding agents and disintegrating agents.
Claim 12
Dependent Claim
35 words
The ocular device defined by claim 1 wherein the drug formulation is microencapsulated with a material to render the drug formulation insoluble in water, the microcapsules being dispersed in the drug release rate controlling material.
References Cited (Backward Citations)
US273410A
Cited
DE1003914B
Cited
US3113076A
Cited
US3297033A
Cited
US3249109A
Cited
US3329574A
Cited
US3444858A
Cited
US3574820A
Cited
US3598122A
Cited
US3598123A
Cited
US3598122B1
Cited
US3618604A
Cited
US3630200A
Cited
US3773919A
Cited
US3640741A
Cited
US3625214A
Cited
US3641237A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-11-23 | 1980-05-24 | 1980-11-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-11-23 | 1984-05-24 | 1984-11-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-11-23 | 1988-05-24 | 1988-11-23 | $7700.00 | Window Closed / Lapsed |